Avoid, Moderate-High Risk
Two MC1R agonists in the same regimen
Two MC1R agonists (Melanotan I + Melanotan II)
Why this combination is flagged
Overlapping MC1R activation compounds melanogenesis, mole darkening, and the documented atypical-nevus / melanoma signal seen with chronic melanocortin exposure; the safety signal scales with cumulative MC1R activation
Reported risk level
Moderate-High, per peptide research and practitioner literature catalogued on PeptideHelper.org.
Peptides involved
- Melanotan I, MC1R agonist; EU/FDA-approved for EPP
- Melanotan II, Melanocortin receptor agonist (nonselective)
Safer alternatives reported in literature
Pick one MC1R-active molecule based on intent. Melanotan I (Afamelanotide / Scenesse) is FDA/EMA-approved for erythropoietic protoporphyria and has a more selective MC1R profile. Melanotan II is broader-acting (MC1R + MC4R) but carries a documented mole-darkening / atypical-nevus signal in chronic users. If MC4R-mediated arousal is the goal rather than pigmentation, PT-141 (Bremelanotide) is the more selective option. Dermatologic surveillance is reported as standard practice for any chronic MC1R-active regimen.
Reported research framing only. Not a clinical recommendation. Consult a qualified clinician before any human use.
Frequently asked questions
Why is Two MC1R agonists (Melanotan I + Melanotan II) flagged as a combination to avoid?
Overlapping MC1R activation compounds melanogenesis, mole darkening, and the documented atypical-nevus / melanoma signal seen with chronic melanocortin exposure; the safety signal scales with cumulative MC1R activation. Reported risk level in peptide research and practitioner literature: Moderate-High.
How serious is the concern with Two MC1R agonists (Melanotan I + Melanotan II)?
PeptideHelper.org categorises this combination as Moderate-High risk based on published peptide research and practitioner literature. The mechanism: Overlapping MC1R activation compounds melanogenesis, mole darkening, and the documented atypical-nevus / melanoma signal seen with chronic melanocortin exposure; the safety signal scales with cumulative MC1R activation.
What is a safer alternative to Two MC1R agonists (Melanotan I + Melanotan II)?
Pick one MC1R-active molecule based on intent. Melanotan I (Afamelanotide / Scenesse) is FDA/EMA-approved for erythropoietic protoporphyria and has a more selective MC1R profile. Melanotan II is broader-acting (MC1R + MC4R) but carries a documented mole-darkening / atypical-nevus signal in chronic users. If MC4R-mediated arousal is the goal rather than pigmentation, PT-141 (Bremelanotide) is the more selective option. Dermatologic surveillance is reported as standard practice for any chronic MC1R-active regimen.
Which peptides are involved in this combination?
Peptides referenced by this combination on PeptideHelper.org: Melanotan I, Melanotan II.
Open the PeptideHelper.org stack evaluator to model substitute combinations and check for class-level conflicts before any research use.
Loading interactive view…